TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01809210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: 2 x 25mg capsules bd continuously in cohort 1 (with gemcitabine and cisplatin). If tolerated - next cohort 3 x 25mg capsules bd continuously. if higher doses are explored, required number of capsules will be provided. Option to administer on D2-19 of each 21 day cycle if required to assess tolerability of combinations with chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1250 mg/m2 iv on Day 1 and 8 of each 21 day cycle. If combination not tolerated, option to give 1000 mg/m2 iv on Day 1 and Day 8 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2 iv on Day 1 of each 21 day cycle. If combination not tolerated, option to give 50 mg/m2 iv on Day 1 or 25mg/m2 iv on Day 1 and Day 8 of each 21 day cycle
Study: NCT00731367

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel Ag Gelled
Description: AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel Ag Adherent
Description: AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing.
Study: NCT01388257

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: All types of surgery procedures
Description: All types of surgery procedures used for anoperineal fistula repair. Surgery procedures include fistulotomy, biological glue, rectal advancement flap and plug.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Simple seton drain removal
Description: Patients are simply followed after seton drain removal.
Study: NCT01809210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: If it is not possible to identify a tolerable combination of selumetinib, gemcitabine and cisplatin, cisplatin may be replaced with carboplatin (AUC5) iv on Day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Gemcitabine may be replaced with pemetrexed 500 mg/m2 iv on Day 1 of each 21 day cycle.
Study: NCT00315627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islet transplantation
Description: Islet transplantation
Study: NCT03081208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nolasiban 900mg
Description: Nolasiban dispersible tablets for single oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dispersible tablets for single oral administration
Study: NCT01970917

Intervention type: DEVICE
Group type: OTHER
Intervention: Olixia pure eye drops

Intervention type: DEVICE
Group type: OTHER
Intervention: Olixia pure eye drops

Intervention type: DEVICE
Group type: OTHER
Intervention: Placebo
Description: 0.9% physiological saline solution

Intervention type: DEVICE
Group type: OTHER
Intervention: Placebo
Description: 0.9% physiological saline solution
Study: NCT02212236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological preparation
Description: Ninety-minute, group-based psychological preparation delivered prior to haematopoietic stem cell transplantation aiming at alleviating psychological distress during the procedure by enhancing perceptions of the procedure and fostering more helpful coping.
Study: NCT03852745

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy
Description: cognitive behavioral therapy; focus on learning skills including acceptance and commitment
Study: NCT01842555

Intervention type: OTHER
Intervention: Registry
Description: Registry
Study: NCT01915264

Intervention type: DRUG
Intervention: Acarbose/Metformin (Glucobay M, BAY81-9783)
Description: Acarbose (25/50mg) and Metformin (500mg) in fixed dose combination.
Study: NCT02284971

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDX1127

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDX1127

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDX1127

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Study: NCT04509739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: At 9 months of age, families will start the 12 - session intervention in a controlled laboratory space. In the initial session, caregivers will be given a brief orientation to intervention, including introducing them to the musical toys they will be using during the sessions with their infants and the lab environment. They will also be trained techniques through which they can synchronize the infant's movements to the experimenter's movements, such as clapping hand, tapping feet.~The remaining sessions will be scheduled in groups of 2-3 infant/parent dyads. In each session, a music CD with 15 minutes of selected children's music will be played and a musically trained experimenter will facilitate the sessions to engage the infants and parents to move to musical beats, using different musical toys, such as infant drums and maracas. Parents will be instructed to not to repeat any of these activities outside of the lab setting for the period of the study.
Study: NCT04099251

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT01607840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: delivery of transcranial direct current stimulation or sham for 20 to 60 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: delivery of transcranial direct current stimulation or sham for 20 to 60 minutes

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: delivery of transcranial direct current stimulation or sham for 20 to 60 minutes
Study: NCT04050371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate
Description: All study participants received daily observed therapy with FTC/TDF.
Study: NCT01314612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Insomnia and Nightmare Group
Description: Group based cognitive-behavioral therapy meeting weekly for 90 minutes over the course of 9 weeks. Utilizes stimulus control, sleep scheduling, and progressive muscle relaxation to address symptoms of insomnia. Imagery rehearsal and rescripting are used to address nightmare symptoms.
Study: NCT02269826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagisan® Moisturising Cream
Description: Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gynomunal® vaginal gel
Description: Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).
Study: NCT02029339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous topical triple-tube irrigation and suction
Description: The triple-tube device was continuous operated: instilled the topical solution through the washing tube, delivered negative pressure therapy at 100 - 125 mmHg continuously through the inner tube of sleeve tubes through the central negative pressure device in the wall of the ward. The outer tube was used for normalize and balance the distribution of the negative pressure around the inner tube to allow the solution to penetrate through the dressing to cover the wound, and protecting the inner tube from getting stuck with the sucked tissue. All tubes are all commercially available (Medical Silicone Tubing, Forbest Manufacturing Co., Ltd, China).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: Debridement, offloading, standard moist wound care, and conventional NPWT without continuous irrigation are the fundamental SOC for Open Abdomen with complicated abdominal infections.
Study: NCT02417844

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamsulosin (Astellas)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin HCL
Study: NCT00988325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamiflu
Description: oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamiflu
Description: oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamiflu
Description: oral repeating dose
Study: NCT00728078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: thalidomide 50mg tid for 6 months
Study: NCT01785095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSH (Follicle Stimulating Hormone)
Study: NCT03124238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Massage therapy localized to the back of the individuals for a duration of 30 minutes
Study: NCT03686488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS 102
Description: TAS 102 35 mg will be administered orally twice daily every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA]
Description: Ramucirumab 8 milligrams/kilogram will be administered as a 60 minute intravenous (IV) infusion every 2 weeks.
Study: NCT04096365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subcostal Temporary Extracardiac Pacing Lead
Description: The StealthTrac Lead is designed to facilitate extracardiac temporary ventricular pacing and sensing. The distal end of the StealthTrac Lead is designed to reside within the connective tissue of the anterior mediastinum outside the pericardium. The StealthTrac Lead is delivered using the MACH I Delivery Tool, which is designed to facilitate insertion of the StealthTrac Lead through a small skin incision parallel to the sternum, without the need for fluoroscopic guidance.
Study: NCT02401529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV dexamethasone
Description: 0.15 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Description: 0.25mg/kg/day for 7 days then tapering for next 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: acetaminophen 15 mg/kg/dose every 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: acetaminophen 15 mg/kg/dose every 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV saline
Description: IV saline
Study: NCT02968940

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10 mg/kg intravenously (IV) every 2 weeks
Study: NCT01871857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline and epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline and epinephrine
Study: NCT02670343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Testosterone Undecanoate
Description: Subjects will receive a single dose containing 158 mg of testosterone undecanoate, equivalent to 200 mg testosterone.
Study: NCT02933580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: Participants will receive a single oral dose (tablets) of JNJ-56136379 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: Participants will receive a single oral dose (tablets) of JNJ-56136379 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: Participants will receive a single oral dose (tablets) of JNJ-56136379 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: Participants will receive a single oral dose (tablets) of JNJ-56136379 on Day 1.
Study: NCT02968940

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy (HFRT)
Description: Hypofractionated radiation therapy to a total dose of 30 Gy, delivered in 6 Gy per fraction for 5 consecutive daily fractions
Study: NCT02938728

Intervention type: OTHER
Intervention: Biopsies
Study: NCT01220674

Intervention type: OTHER
Intervention: cognitive testing
Description: computer-based cognitive assessment

Intervention type: OTHER
Intervention: cognitive testing
Description: computer-based cognitive assessment
Study: NCT03644134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of physiological stress and sleep pattern
Description: The personalized intervention consists of (i) information session (ii) pre-assessment (first assessment) of stress and recovery levels, and sleep patterns (iii) individual feedback sessions and action plans based on the outcomes of the initial assessment (iv) monitoring and follow-ups (v) post-assessment (second assessment) of stress and recovery levels and sleep patterns.
Study: NCT04581681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behaviour Therapy for Perinatal Anxiety (CBT-PA)
Description: The 6-session group CBT intervention for perinatal anxiety has been formalized with session guides for the facilitators and a workbook, Overcoming Anxiety in Pregnancy and Postpartum (Furer \& Reynolds, 2015), developed by members of our Anxiety Disorders Clinic. There are 6 core modules covered over the 6 treatment sessions, including: (1) Understanding anxiety during pregnancy and postpartum, (2) self-care, (3) setting goals and facing fears, (4) nurturing the developing relationship with baby, (5) coping with negative thoughts and worries, and (6) relapse prevention. Content is based on general principles of CBT for anxiety but specific themes and examples are geared towards the pregnancy and postpartum periods. Distorted cognitions are also explored, with an additional focus on beliefs about motherhood and perfectionism. Due to the COVID-19 pandemic, the intervention will be conducted via a hospital-approved video-conferencing platform.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No treatment (waitlist control)
Description: Patients in this condition are randomly assigned to a waitlist control condition before receiving treatment.
Study: NCT03421990

Intervention type: PROCEDURE
Intervention: General anesthesia
Description: general anesthesia and regional anesthesia techniques are used
Study: NCT04921995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 1. Chemotherapy (including but not limited to following):~   GP regimen: gemcitabine 1000mg/m2 d1, d8 + cisplatin 25 mg/m2 d1-3, every 3 weeks for 4-6 cycles; GX regimen: gemcitabine 800mg/m2 d1 + capecitabine 750 mg/m2 d1-14, every 3 weeks for 4-6 cycles.~   Capecitabine: 750 mg/m2 d1-14, every 3 weeks until unacceptable toxicities or patient's withdraw.~2. anti-PD-1 antibody: Tislelizumab concurrently with chemotherapy: 200mg, every 3 weeks for 12 weeks. Tislelizumab in maintenance period: 200mg every 3 weeks or 400mg every 6 weeks, until one year or disease progression, or in the case of intolerable toxicities.
Study: NCT02933580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo tablets on Day 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo tablets on Day 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo tablets on Day 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo tablets on Day 1.
Study: NCT03376438

Intervention type: OTHER
Intervention: Prospective observational cohorts
Description: Patients with AF or SVT that is significant enough to consider prenatal treatment are eligible for enrollment. Management decisions are made at each patient encounter by the primary physician based on clinical findings and may include: 1) no antiarrhythmic treatment; 2) transplacental antiarrhythmic treatment; 3) direct fetal antiarrhythmic treatment; 4) delivery. Patients enrolled in the FAST Registry will be followed from the time of enrollment until the baby is discharged after birth.
Study: NCT01542671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: * Lifestyle Counselor meetings at baseline, 6 months, and 12 months~* Structured eating plan~* Tailored nutritional and exercise tips. Weekly: months 1-12, biweekly: months 13-18, and monthly: months 19-24.~* Monthly Motivational phone calls with Lifestyle Counselor for the first year~* 4 informational DVDs over the two year period~* Feedback on submitted food and exercise journals
Study: NCT02816684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pegasys-VR
Description: Pegasys-VR uses artificially intelligent avatars and serious game technology to assist children in the acquisition and use of social skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Effectiveness Therapy for Children
Description: Group social skills training, peer generalization sessions, individual exposure therapy
Study: NCT01542671

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: * Lifestyle Counselor meetings at baseline, 6 months, and 12 months~* Structured eating plan~* 5 informational NIDDK mailings over the two year period
Study: NCT04040868

Intervention type: DEVICE
Group type: OTHER
Intervention: the TiRobot system
Description: The TiRobot system (TINAVI Medical Technologies Co. Ltd.) is a multi-indication orthopedic surgical robot that can be used in spinal, pelvic, and limb surgeries performed via an open or a minimally invasive approach

Intervention type: DEVICE
Group type: OTHER
Intervention: Freehand
Description: conventional fluoroscopy-assisted
Study: NCT01565837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 10mg/kg administered intravenously over 90-minute period every 3 weeks for a total of four doses as tolerated. Maintenance ipilimumab (10 mg/kg intravenously every 3 months) will be administered beginning Week 24, as long as there is clinical benefit in the opinion of the investigator using immune related response criteria, and there are no novel or unexpected Grade 3 or 4 toxicities.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiosurgery (SART)
Description: Definitive radiotherapy will be administered to up to 1-5 lesions using SART techniques after initial dose of ipilimumab. Radiotherapy will be timed before start of 3rd cycle of ipilimumab treatment to maximize synergy (week 6).
Study: NCT02525315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation: rTMS
Description: 4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
Study: NCT02369562

Intervention type: PROCEDURE
Intervention: Evaluation of the failure rate of dental implants
Description: Evaluation of the failure rate of dental implants, from the time of implant insertion (any time between 1980 and August 31st 2014) until September 2015
Study: NCT04105829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bond-a braid
Description: Stainless steel lingual retainer application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EverStick-Ortho
Description: Fiber reinforced lingual retainer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ribbond
Description: Fiber reinforced lingual retainer
Study: NCT02763761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab + Prednisone
Description: Prednisone dose will be decreased every 3 days for 18 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone + Prednisone
Description: Prednisone dose will be decreased every 4 days for 40 days
Study: NCT06087003

Intervention type: DRUG
Intervention: Basiliximab Injection
Description: As an induction treatment for kidney transplantation

Intervention type: DRUG
Intervention: rabbit ATG
Description: As an induction treatment for kidney transplantation
Study: NCT06353230

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injection 5% phenol in almond oil
Description: Group A were given 5% phenol in almond oil

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: injection 5% phenol in almond oil
Description: Group A were given 5% phenol in almond oil

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: injection 5% phenol in almond oil
Description: Group A were given 5% phenol in almond oil

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injection 15% hypertonic saline
Description: Group B were given hypertonic saline

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: injection 15% hypertonic saline
Description: Group B were given hypertonic saline

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: injection 15% hypertonic saline
Description: Group B were given hypertonic saline

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injection 50% dextrose water
Description: group C were given 50% dextrose water

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: injection 50% dextrose water
Description: group C were given 50% dextrose water

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: injection 50% dextrose water
Description: group C were given 50% dextrose water
Study: NCT01452009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Ophthalmic Solution, 0.004% (New Formulation)
Description: Travoprost Ophthalmic Solution, 0.004% given one drop once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRAVATAN®
Description: TRAVATAN® administered one drop once daily